A5102846287- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- Immunotherapy and Immune Responses
- Lymphoma Diagnosis and Treatment
- Lung Cancer Research Studies
- Chronic Lymphocytic Leukemia Research
- Advanced Breast Cancer Therapies
- Immune cells in cancer
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Chronic Myeloid Leukemia Treatments
- Myasthenia Gravis and Thymoma
- HER2/EGFR in Cancer Research
- Immune Cell Function and Interaction
- Cancer survivorship and care
- Acute Myeloid Leukemia Research
- Pituitary Gland Disorders and Treatments
- Cancer Diagnosis and Treatment
- Gastrointestinal Tumor Research and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Prostate Cancer Treatment and Research
- Tuberous Sclerosis Complex Research
- Cancer-related Molecular Pathways
Inha University Hospital
2017-2025
Inha University
2017-2025
Weatherford College
2020
Sungkyunkwan University
2015-2019
Samsung Medical Center
2015-2019
Limited treatment options exist for patients with thymic epithelial tumor (TET) whose disease progresses after platinum-based chemotherapy. We conducted a phase II study of pembrolizumab in TET to evaluate its efficacy and safety.Patients histologically confirmed progressed at least one line chemotherapy were eligible the study. Patients excluded if they had an active autoimmune requiring systemic within past year or documented history clinically severe disease. received 200 mg intravenously...
Abstract Purpose: To investigate blood-based dynamic biomarkers that predict responses to anti–programmed cell death protein 1 (PD-1) therapy in solid tumors. Experimental Design: Preplanned biomarker analysis was performed as part of a phase II clinical trial (NCT02607631) patients with metastatic or refractory thymic epithelial tumors (TETs; n = 31) who received pembrolizumab. The further tested an independent cohort prospectively recruited non–small lung cancer (NSCLC) pembrolizumab...
Abstract Purpose This network meta-analysis aimed to evaluate the relative efficacy of systemic treatments in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL), focusing on key genetic mutations, specifically 17p deletion and TP53 mutations. Methods We conducted a systematic literature review identify all publicly available randomized controlled trials (RCTs) using PubMed, EMBASE, Cochrane database, meeting abstracts published through December 2023. A Bayesian was...
Although anti-programmed death-1 (PD-1) treatment has shown remarkable anti-tumor efficacy, immune-related adverse events (irAEs) develop with heterogeneous clinical manifestations. However, the immunological understanding of irAEs is currently limited. In present study, we analyzed peripheral blood T cells obtained from cancer patients who received anti-PD-1 to determine characteristics irAEs. This study included 31 refractory thymic epithelial tumor (TET) were enrolled in a phase II trial...
8521 Background: No standard treatment exists for patients with thymic epithelial tumor (TET) who progress after platinum-containing chemotherapy. We conducted a phase II study of pembrolizumab in TET to evaluate the efficacy and safety. Methods: Between March 2016 December 2016, histologically confirmed progressed chemotherapy were eligible. Patients excluded if they had an active autoimmune disease requiring systemic within past one year. received 200mg intravenously every 3 weeks until...
The BRAF inhibitors vemurafenib and dabrafenib are currently the standard treatment for metastatic melanoma with V600 mutations. However, given rarity of noncutaneous melanoma, including acral mucosal subtypes, efficacy this subset patients has not been extensively investigated. Acquired resistance generally appears 6 to 8 months after a inhibitor, mechanism is well established.We examined outcomes diagnosed treated at Samsung Medical Center between April 2013 December 2015. We analyzed...
While concerns regarding trastuzumab-related cardiac dysfunction (TRCD) in patients with breast cancer are increasing, there is a lack of evidence supporting the current recommendations for TRCD monitoring. We aimed to investigate clinical predictors adjuvant setting human epidermal growth factor receptor 2-positive patients.From August 2003 April 2016, consecutive 998 who were treated trastuzumab retrospectively evaluated. was defined as decrease ≥10% left ventricular ejection fraction...
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death globally. Mechanistic target rapamycin (mTOR) frequently up-regulated in HCC and plays an important role tumorigenesis. Tumors with loss tuberous sclerosis complex 2 (TSC2), negative regulator mTOR signaling, tend to respond well inhibitors. We analyzed TSC2 expression status Korean patients evaluated the correlation between response inhibitor, everolimus.We retrospectively assessed 36 advanced who had received...
Hyperprogressive disease (HPD) is a distinct pattern of progression characterized by acceleration tumor growth after treatment with anti-PD-1/PD-L1 Abs.However, the immunological characteristics have not been fully elucidated in patients HPD.We prospectively recruited metastatic non-small cell lung cancer treated Abs between April 2015 and 2018, collected peripheral blood before 7-days post-treatment.HPD was defined as ≥2-fold increase both kinetics rate pre-treatment...
Purpose The optimal cytotoxic regimens have not been established for patients with non-small cell lung cancer (NSCLC) who develop disease progression on first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Materials and Methods We conducted a multi-center randomized phase II trial to compare the clinical outcomes between pemetrexed plus cisplatin combination therapy followed by maintenance (PC) monotherapy (P) after failure of EGFR-TKI. primary objective was...
The purpose of this study was to assess the tumor characteristics and long-term clinical outcomes adjuvant treatments after surgery with a curative aim for patients breast cancer who are 65 years older.Patients underwent from 2000 2009 were analyzed (n=4,388). Tumor survival outcome compared by dividing into two age groups (< ≥ old). Kaplan-Meier method used comparison rates log-rank test, Cox regression model examine effect variables.Among 4,388 invasive cancer, 317 (7.2%) or older median...